For almost two decades CVS Health has argued that the best way to run American healthcare is to own as much of it as possible. On 4 November it changed its mind. The company said it will split into two listed businesses: CVS Pharmacy, which will take the retail stores, the mail-order pharmacy, MinuteClinic and the Health100 technology unit, and a slimmer CVS Health that keeps Aetna, the Caremark pharmacy benefit manager, specialty pharmacy, Oak Street Health and Signify Health.
Shareholders will receive stock in both companies in a separation the group expects to be tax-free and complete in the first half of 2028. David Joyner, chief executive since late 2024, will continue to lead CVS Health. Prem Shah, the group president who has worked across the benefits, specialty and retail sides since 2013, will run CVS Pharmacy.
The market’s verdict was harsh. CVS shares fell 12.6% to $79.94 on the day, erasing a large slice of a rally that had lifted the stock about 15% this year.
A Strong Quarter, Overshadowed
The timing was odd, because the numbers released alongside the plan were good. Third-quarter revenue rose 5.4% to $108.4 billion and adjusted earnings per share reached $2.09, comfortably ahead of the roughly $1.65 analysts had expected. CVS raised its full-year adjusted EPS guidance to at least $8.20, from a range of $7.90 to $8.10, lifted its revenue outlook to at least $420 billion and said share buybacks would resume this quarter after it hit its debt target early. It also pointed to at least $8.65 of adjusted EPS in 2027.
Investors chose to focus on what the breakup says instead. A UBS analyst called the announcement a surprise and said it looked like a defensive response to regulation rather than an attack on new markets. Joyner rejected that reading, telling analysts the company was not acting out of distress and that two focused businesses would move faster than one.
Why the Integrated Model Lost Its Shine
The logic of the old CVS was simple. Buy Caremark, which decides which drugs employers’ plans cover and where members fill them, then add Aetna, closed in 2018 in a deal worth close to $70 billion before debt, then add primary care through Oak Street and home visits through Signify. Each piece was meant to feed the others with patients, data and margin.
Several things went wrong. Medicare Advantage costs surged in 2023 and 2024, hammering Aetna’s profits and costing Karen Lynch her job. The care delivery assets struggled to earn back their price. And lawmakers turned on the model itself. Arkansas and Tennessee have passed laws that stop companies from owning both a benefit manager and the pharmacies it steers patients towards, and CVS is fighting them in court. Arielle Trzcinski of Forrester said the split unwinds a central part of the case for the acquisitions.
Notably, the breakup does not touch the combination that draws the most federal criticism. Aetna and Caremark stay together, so the insurer-owned benefit manager survives. What gets cut loose is the store estate, a business squeezed by thin reimbursement, theft and closures, which may now be valued on its own merits and could find it easier to serve rival benefit managers.
What the CVS Breakup Means for Your Business
The impact. Nothing changes on day one: CVS says prescriptions, benefits and clinic services continue as normal until 2028. The longer-term effect falls hardest on employers that buy medical cover from Aetna and pharmacy benefits from Caremark, and on those that depend on CVS stores or MinuteClinic in their networks. Once the retail chain is independent, the commercial ties between your benefit manager and its biggest pharmacy partner become an arm’s-length contract, and pricing, network access and rebate terms can move. Healthcare suppliers that sell into CVS will face two procurement teams with different priorities. For boards elsewhere, the lesson is wider: a conglomerate discount that management ignores eventually gets forced into the open, by investors or by regulators.
What to do now:
1. Ask your benefits consultant to map which of your health and pharmacy contracts touch Aetna, Caremark or CVS retail, and when each renews before and after 2028.
2. Push Caremark for written commitments on retail network access, dispensing fees and rebate pass-through that survive the separation.
3. Use the uncertainty to run a competitive benefit manager review, including transparent pass-through models, ahead of your next renewal.
4. If you rely on MinuteClinic or CVS stores for on-site care, vaccinations or employee programmes, confirm how those agreements will be assigned once CVS Pharmacy stands alone.
5. For your own board: test whether any of your business units would be worth more separately, before an activist or a regulator asks the question for you.
CVS spent more than $100 billion, across Caremark, Aetna, Oak Street and Signify, assembling a healthcare empire. Its decision to take it apart is the clearest sign yet that owning every link in the chain is no longer a competitive advantage in its own right.
